• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

鼠肿瘤血管系统表达 NKG2D 配体,并可被嵌合 NKG2D 修饰的 T 细胞靶向。

Mouse tumor vasculature expresses NKG2D ligands and can be targeted by chimeric NKG2D-modified T cells.

机构信息

Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Lebanon, NH 03756, USA.

出版信息

J Immunol. 2013 Mar 1;190(5):2455-63. doi: 10.4049/jimmunol.1201314. Epub 2013 Jan 25.

DOI:10.4049/jimmunol.1201314
PMID:23355740
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3665362/
Abstract

Tumor angiogenesis plays an important role in the development of solid tumors, and targeting the tumor vasculature has emerged as a strategy to prevent growth and progression of solid tumors. In this study, we show that murine tumor vasculature expresses Rae1, a ligand for a stimulatory NK receptor NKG2D. By genetic modification of T cells with an NKG2D-based chimeric Ag receptor, referred to as chNKG2D in which the NKG2D receptor is fused to the signaling domain of CD3ζ-chain, T cells were capable of targeting tumor vasculature leading to reduced tumor angiogenesis and tumor growth. This occurred even in tumors where the tumor cells themselves did not express NKG2D ligands. H5V, an endothelial cell line, expresses Rae1 and was lysed by chNKG2D-bearing T cells in a perforin-dependent manner. In vitro capillary tube formation was inhibited by chNKG2D T cells through IFN-γ and cell-cell contact mechanisms. The in vivo antiangiogenesis effects mediated by chNKG2D-bearing T cells at the tumor site were dependent on IFN-γ and perforin. These results provide a novel mechanism for NKG2D-based targeting of solid tumors.

摘要

肿瘤血管生成在实体瘤的发展中起着重要作用,针对肿瘤血管已成为防止实体瘤生长和进展的一种策略。在这项研究中,我们表明,鼠类肿瘤血管表达 Rae1,这是一种刺激 NK 受体 NKG2D 的配体。通过用基于 NKG2D 的嵌合 Ag 受体(称为 chNKG2D,其中 NKG2D 受体与 CD3ζ 链的信号域融合)对 T 细胞进行基因修饰,T 细胞能够靶向肿瘤血管,导致肿瘤血管生成减少和肿瘤生长减少。即使在肿瘤细胞本身不表达 NKG2D 配体的肿瘤中,也会发生这种情况。H5V 是一种内皮细胞系,表达 Rae1,并通过 chNKG2D 携带的 T 细胞以穿孔素依赖的方式被裂解。chNKG2D T 细胞通过 IFN-γ 和细胞-细胞接触机制抑制体外毛细血管形成。在肿瘤部位由 chNKG2D 携带的 T 细胞介导的抗血管生成作用依赖于 IFN-γ 和穿孔素。这些结果为基于 NKG2D 的实体瘤靶向提供了一种新的机制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b2f/3665362/192eb495bd28/nihms-432525-f0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b2f/3665362/4a48f9ab9197/nihms-432525-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b2f/3665362/a96094299323/nihms-432525-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b2f/3665362/28a2dc2f605b/nihms-432525-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b2f/3665362/c3d0abef8a9e/nihms-432525-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b2f/3665362/26292d2133a6/nihms-432525-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b2f/3665362/880a2adb17b0/nihms-432525-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b2f/3665362/192eb495bd28/nihms-432525-f0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b2f/3665362/4a48f9ab9197/nihms-432525-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b2f/3665362/a96094299323/nihms-432525-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b2f/3665362/28a2dc2f605b/nihms-432525-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b2f/3665362/c3d0abef8a9e/nihms-432525-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b2f/3665362/26292d2133a6/nihms-432525-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b2f/3665362/880a2adb17b0/nihms-432525-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b2f/3665362/192eb495bd28/nihms-432525-f0007.jpg

相似文献

1
Mouse tumor vasculature expresses NKG2D ligands and can be targeted by chimeric NKG2D-modified T cells.鼠肿瘤血管系统表达 NKG2D 配体,并可被嵌合 NKG2D 修饰的 T 细胞靶向。
J Immunol. 2013 Mar 1;190(5):2455-63. doi: 10.4049/jimmunol.1201314. Epub 2013 Jan 25.
2
Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer.携带嵌合NKG2D受体的T细胞作为卵巢癌的免疫疗法。
Cancer Res. 2007 May 15;67(10):5003-8. doi: 10.1158/0008-5472.CAN-06-4047.
3
Chimeric NKG2D T cells require both T cell- and host-derived cytokine secretion and perforin expression to increase tumor antigen presentation and systemic immunity.嵌合NKG2D T细胞需要T细胞和宿主来源的细胞因子分泌以及穿孔素表达,以增加肿瘤抗原呈递和全身免疫。
J Immunol. 2009 Aug 15;183(4):2365-72. doi: 10.4049/jimmunol.0900721. Epub 2009 Jul 22.
4
Chimeric NKG2D modified T cells inhibit systemic T-cell lymphoma growth in a manner involving multiple cytokines and cytotoxic pathways.嵌合型NKG2D修饰的T细胞通过涉及多种细胞因子和细胞毒性途径的方式抑制系统性T细胞淋巴瘤的生长。
Cancer Res. 2007 Nov 15;67(22):11029-36. doi: 10.1158/0008-5472.CAN-07-2251.
5
Chimeric NKG2D receptor-expressing T cells as an immunotherapy for multiple myeloma.表达嵌合NKG2D受体的T细胞作为多发性骨髓瘤的免疫疗法。
Exp Hematol. 2008 Oct;36(10):1318-28. doi: 10.1016/j.exphem.2008.04.010. Epub 2008 Jul 2.
6
Treatment of multiple myeloma with adoptively transferred chimeric NKG2D receptor-expressing T cells.嵌合型 NKG2D 受体表达 T 细胞过继转移治疗多发性骨髓瘤。
Gene Ther. 2011 May;18(5):509-16. doi: 10.1038/gt.2010.174. Epub 2011 Jan 6.
7
RAE1 ligands for the NKG2D receptor are regulated by STING-dependent DNA sensor pathways in lymphoma.淋巴瘤中 NKG2D 受体的 RAE1 配体受 STING 依赖性 DNA 传感器途径的调控。
Cancer Res. 2014 Apr 15;74(8):2193-2203. doi: 10.1158/0008-5472.CAN-13-1703. Epub 2014 Mar 3.
8
Chimeric NKG2D expressing T cells eliminate immunosuppression and activate immunity within the ovarian tumor microenvironment.表达嵌合NKG2D的T细胞可消除免疫抑制并激活卵巢肿瘤微环境中的免疫反应。
J Immunol. 2009 Dec 1;183(11):6939-47. doi: 10.4049/jimmunol.0902000. Epub 2009 Nov 13.
9
Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells.使用双特异性 NK 受体融合蛋白的癌症免疫疗法,该融合蛋白同时结合 T 细胞和肿瘤细胞。
Cancer Res. 2011 Mar 15;71(6):2066-76. doi: 10.1158/0008-5472.CAN-10-3200. Epub 2011 Jan 31.
10
Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor.通过用嵌合NKG2D受体对原代人T细胞进行基因改造来产生抗肿瘤反应。
Cancer Res. 2006 Jun 1;66(11):5927-33. doi: 10.1158/0008-5472.CAN-06-0130.

引用本文的文献

1
Downregulation of MICA/MICB improves cell persistence and clinical activity of NKG2DL CAR T-cells in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic neoplasia.MICA/MICB的下调可改善复发或难治性急性髓系白血病或骨髓增生异常肿瘤患者中NKG2DL嵌合抗原受体T细胞的细胞持久性和临床活性。
Leukemia. 2025 Sep 15. doi: 10.1038/s41375-025-02767-4.
2
An Immunomodulating Peptide with Potential to Promote Anticancer Immunity Without Compromising Immune Tolerance.一种具有促进抗癌免疫而不损害免疫耐受潜力的免疫调节肽。
Biomedicines. 2025 Aug 5;13(8):1908. doi: 10.3390/biomedicines13081908.
3
Synthetic NKG2D receptor (SNR) armored CAR-T cells overcome antigen heterogeneity of solid tumor.

本文引用的文献

1
The parallel lives of angiogenesis and immunosuppression: cancer and other tales.血管生成和免疫抑制的平行生活:癌症和其他故事。
Nat Rev Immunol. 2011 Sep 23;11(10):702-11. doi: 10.1038/nri3064.
2
Pathogenesis of Takayasu's arteritis: a 2011 update.Takayasu 动脉炎的发病机制:2011 年更新。
Autoimmun Rev. 2011 Nov;11(1):61-7. doi: 10.1016/j.autrev.2011.08.001. Epub 2011 Aug 9.
3
Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells.肿瘤缺氧通过 CCL28 和 T(调节)细胞促进耐受和血管生成。
合成NKG2D受体(SNR)武装的嵌合抗原受体T细胞(CAR-T细胞)克服实体瘤的抗原异质性。
Cell Oncol (Dordr). 2025 Jun 19. doi: 10.1007/s13402-025-01066-5.
4
Harnessing NKG2D CAR-T cells with radiotherapy: a novel approach for esophageal squamous cell carcinoma treatment.联合放疗利用NKG2D嵌合抗原受体T细胞:一种治疗食管鳞状细胞癌的新方法。
Front Immunol. 2025 May 29;16:1589379. doi: 10.3389/fimmu.2025.1589379. eCollection 2025.
5
23ME-01473, an Fc Effector-Enhanced Anti-ULBP6/2/5 Antibody, Restores NK Cell-Mediated Antitumor Immunity through NKG2D and FcγRIIIa Activation.23ME - 01473,一种Fc效应增强型抗ULBP6/2/5抗体,通过激活NKG2D和FcγRIIIa恢复自然杀伤细胞介导的抗肿瘤免疫。
Cancer Res Commun. 2025 Mar 1;5(3):476-495. doi: 10.1158/2767-9764.CRC-24-0478.
6
The current state of knowledge on the role of NKG2D ligands in multiple sclerosis and other autoimmune diseases.自然杀伤细胞2D(NKG2D)配体在多发性硬化症和其他自身免疫性疾病中的作用的当前知识状态。
Front Mol Neurosci. 2025 Jan 10;17:1493308. doi: 10.3389/fnmol.2024.1493308. eCollection 2024.
7
Regulatory T cells and immune escape in HCC: understanding the tumor microenvironment and advancing CAR-T cell therapy.调节性 T 细胞与 HCC 免疫逃逸:深入了解肿瘤微环境并推进 CAR-T 细胞治疗。
Front Immunol. 2024 Jul 29;15:1431211. doi: 10.3389/fimmu.2024.1431211. eCollection 2024.
8
Natural Receptor- and Ligand-Based Chimeric Antigen Receptors: Strategies Using Natural Ligands and Receptors for Targeted Cell Killing.基于天然受体和配体的嵌合抗原受体:利用天然配体和受体进行靶向细胞杀伤的策略。
Cells. 2021 Dec 22;11(1):21. doi: 10.3390/cells11010021.
9
VEGFR-2 redirected CAR-T cells are functionally impaired by soluble VEGF-A competition for receptor binding.血管内皮生长因子受体 2 重定向嵌合抗原受体 T 细胞的功能因可溶性血管内皮生长因子 A 竞争受体结合而受损。
J Immunother Cancer. 2021 Aug;9(8). doi: 10.1136/jitc-2020-002151.
10
The antigen-binding moiety in the driver's seat of CARs.CAR 中的抗原结合部分位于驾驶座。
Med Res Rev. 2022 Jan;42(1):306-342. doi: 10.1002/med.21818. Epub 2021 May 24.
Nature. 2011 Jul 13;475(7355):226-30. doi: 10.1038/nature10169.
4
Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells.使用双特异性 NK 受体融合蛋白的癌症免疫疗法,该融合蛋白同时结合 T 细胞和肿瘤细胞。
Cancer Res. 2011 Mar 15;71(6):2066-76. doi: 10.1158/0008-5472.CAN-10-3200. Epub 2011 Jan 31.
5
Endothelial cells as key determinants of the tumor microenvironment: interaction with tumor cells, extracellular matrix and immune killer cells.内皮细胞作为肿瘤微环境的关键决定因素:与肿瘤细胞、细胞外基质及免疫杀伤细胞的相互作用
Crit Rev Immunol. 2010;30(6):529-45. doi: 10.1615/critrevimmunol.v30.i6.30.
6
Active immunotherapy induces antibody responses that target tumor angiogenesis.主动免疫疗法可诱导针对肿瘤血管生成的抗体反应。
Cancer Res. 2010 Dec 15;70(24):10150-60. doi: 10.1158/0008-5472.CAN-10-1852.
7
CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation.CD4(+) T 细胞有助于重塑微环境,这是癌基因失活后持续肿瘤消退所必需的。
Cancer Cell. 2010 Nov 16;18(5):485-98. doi: 10.1016/j.ccr.2010.10.002. Epub 2010 Oct 28.
8
Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice.利用针对 VEGFR-2 的基因修饰淋巴细胞的基因治疗抑制了小鼠血管化同种肿瘤的生长。
J Clin Invest. 2010 Nov;120(11):3953-68. doi: 10.1172/JCI43490. Epub 2010 Oct 11.
9
Perivascular T-cell infiltration leads to sustained pulmonary artery remodeling after endothelial cell damage.血管周围 T 细胞浸润导致内皮细胞损伤后肺动脉持续重塑。
Am J Respir Cell Mol Biol. 2011 Jul;45(1):62-71. doi: 10.1165/rcmb.2009-0365OC. Epub 2010 Sep 2.
10
Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer.抗血管生成药物可以增加淋巴细胞浸润到肿瘤中,并增强癌症过继免疫治疗的效果。
Cancer Res. 2010 Aug 1;70(15):6171-80. doi: 10.1158/0008-5472.CAN-10-0153. Epub 2010 Jul 14.